Aptamer-conjugated magnetic nanoparticles enable efficient targeted detection of integrin αvβ3 via magnetic resonance imaging

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 1, 2014, Pages 49-59

  Lim, Eun Kyung ^a   Kim, Bongjune ^a   Choi, Yuna ^b   Ro, Youngjun ^a   Cho, Eun Jin ^b   Lee, Jung Hwan ^c   Ryu, Sung Ho ^c   Suh, Jin Suck ^b,d   Haam, Seungjoo ^a,d   Huh, Yong Min ^b,d  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

angiogenesis; aptamer; integrin avb3; magnetic nanoparticle; magnetic resonance imaging

Indexed keywords

DIAGNOSIS; MAGNETIC RESONANCE IMAGING; TUMORS;

ANGIOGENESIS; APTAMERS; CYTOCOMPATIBILITY; INTEGRINS; MAGNETIC NANO-PARTICLES; MAGNETIC SENSITIVITY; NEO-VASCULARIZATION; TUMOR DIAGNOSIS;

NANOPARTICLES;

APTAMER; MAGNETIC NANOPARTICLE; VITRONECTIN RECEPTOR; CONTRAST MEDIUM; NANOPARTICLE; PEPTIDE APTAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DECOMPOSITION; DRUG CONJUGATION; HYDROGEN BOND; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC FIELD; MALE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NANOEMULSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; STATIC ELECTRICITY; SURFACE CHARGE; SYNTHESIS; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; EXPERIMENTAL NEOPLASM; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PROCEDURES; RADIOGRAPHY; VASCULARIZATION;

ANIMALS; APTAMERS, PEPTIDE; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC FIELDS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84888640357     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34678     Document Type: Article

References (77)

1. Pasqualini R, Koivunen E, Ruoslahti E,. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997; 15 (6): 542-546.
2. Hood JD, Cheresh DA,. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2 (2): 91-100.
3. Hynes R,. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
4. Cai W, Sam Gambhir S, Chen X,. Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques 2005; 39 (6 suppl): S14-S25.
5. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA,. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 108 (18): 2270-2274.
6. Sancey L, Ardisson V, Riou LM, Ahmadi M, Marti-Batlle D, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP,. In vivo imaging of tumor angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 2007; 34 (12): 2037-2047.
7. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005; 2 (3): e70.
8. Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, Boturyn D, Souchier C, Grichine A, Dumy P, et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther 2009; 17 (5): 837-843.
9. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC,. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998; 4 (5): 623-626.
10. Garanger E, Boturyn D, Jin Z, Dumy P, Favrot MC, Coll JL,. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther 2005; 12 (6): 1168-1175.
11. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, Bremner R, Bading JR, Conti PS,. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005; 7 (3): 271-279.
12. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC,. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002; 62 (21): 6146-6151.
13. Schraa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, Meijer DK, de Leij LF, Molema G,. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J Control Release 2002; 83 (2): 241-251.
14. Lim EH, Danthi N, Bednarski M, Li KC,. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 2005; 1 (2): 110-114.
15. Heroux J, Gharib AM, Danthi NS, Cecchini S, Ohayon J, Pettigrew RI,. High-affinity alphavbeta3 integrin targeted optical probe as a new imaging biomarker for early atherosclerosis: Initial studies in Watanabe rabbits. Mol Imaging Biol 2010; 12 (1): 2-8.
16. Schraa AJ, Kok RJ, Botter SM, Withoff S, Meijer DK, de Leij LF, Molema G,. RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells. Int J Cancer 2004; 112 (2): 279-285.
17. Chetty C, Lakka SS, Bhoopathi P, Rao JS,. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010; 127 (5): 1081-1095.
18. Fang C, Zhang M,. Multifunctional magnetic nanoparticles for medical imaging applications. J Mater Chem 2009; 19: 6258-6266.
19. Ko HY, Choi KJ, Lee CH, Kim S,. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 2011; 32 (4): 1130-1138.
20. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo YE, Woolliscroft MJ, Sugai JV, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12 (22): 6677-6686.
21. McCarthy JR, Weissleder R,. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008; 60 (11): 1241-1251.
22. Weissleder R, Mahmood. U,. Molecular imaging. Radiology 2001; 219: 316-333.
23. Cai W, Chen X,. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007; 3 (11): 1840-1854.
24. Weissleder R, Pittet MJ,. Imaging in the era of molecular oncology. Nature 2008; 452 (7187): 580-589.
25. Lim EK, Yang J, Dinney CP, Suh JS, Huh YM, Haam S,. Self-assembled fluorescent magnetic nanoprobes for multimode-biomedical imaging. Biomaterials 2010; 31 (35): 9310-9319.
26. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007; 13 (1): 95-99.
27. Jun Y-w, Huh Y-M, Choi J-s, Lee J-H, Song H-T, Kim S, Yoon S, Kim K-S, Shin J-S, Suh J-S, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005; 127: 5732-5733.
28. Yang J, Gunn J, Dave SR, Zhang M, Wang YA, Gao X,. Ultrasensitive detection and molecular imaging with magnetic nanoparticles. Analyst 2008; 133 (2): 154-160.
29. Yang J, Lee T-I, Lee J, Lim E-K, Hyung W, Lee C-H, Song YJ, Suh J-S, Yoon H-G, Huh Y-M, et al. Synthesis of ultrasensitive magnetic resonance contrast agents for cancer imaging using PEG-fatty acid. Chem Mater 2007; 19: 3870-3876.
30. Park J, Yu MK, Jeong YY, Kim JW, Lee K, Phan VN, Jon S,. Antibiofouling amphiphilic polymer-coated superparamagnetic iron oxide nanoparticles: Synthesis, characterization, and use in cancer imaging in vivo. J Mater Chem 2009; 19 (35): 6412.
31. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K,. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004; 22 (6): 843-850.
32. Choi H, Choi SR, Zhou R, Kung HF, Chen IW,. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004; 11 (9): 996-1004.
33. Yigit MV, Mazumdar D, Lu Y,. MRI detection of thrombin with aptamer functionalized superparamagnetic iron oxide nanoparticles. Bioconjugate Chem 2008; 19: 412-417.
34. Vera DR, Buonocore MH, Wisner ER, Katzberg RW, Stadalnik RC,. A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver. Acad Radiol 1995; 2 (6): 497-506.
35. Penno E, Johnsson C, Johansson L, Ahlstrom H,. Comparison of ultrasmall superparamagnetic iron oxide particles and low molecular weight contrast agents to detect rejecting transplanted hearts with magnetic resonance imaging. Invest Radiol 2005; 40 (10): 648-654.
36. Peldschus K, Schultze A, Nollau P, Kaul M, Schumacher U, Wagener C, Adam G, Ittrich H,. Quantitative MR imaging of targeted SPIO particles on the cell surface and comparison to flow cytometry. Magn Reson Imaging 2010; 28 (4): 599-606.
37. Lim EK, Yang J, Park MY, Park J, Suh JS, Yoon HG, Huh YM, Haam S,. Synthesis of water soluble PEGylated magnetic complexes using mPEG-fatty acid for biomedical applications. Colloids Surf B Biointerfaces 2008; 64 (1): 111-117.
38. Lim E-K, Yang J, Suh J-S, Huh Y-M, Haam S,. Self-labeled magneto nanoprobes using tri-aminated polysorbate 80 for detection of human mesenchymal stem cells. J Mater Chem 2009; 19 (47): 8958.
39. Qiao R, Yang C, Gao M,. Superparamagnetic iron oxide nanoparticles from preparations to in vivo MRI applications. J Mater Chem 2009; 19: 6274-6293.
40. Lanza GM,. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 2002; 106 (22): 2842-2847.
41. Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, Wang YM,. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009; 14 (2): 253-260.
42. Lee J, Yang J, Seo SB, Ko HJ, Suh JS, Huh YM, Haam S,. Smart nanoprobes for ultrasensitive detection of breast cancer via magnetic resonance imaging. Nanotechnology 2008; 19 (48): 485101.
43. Hun X, Zhang Z,. Anti-epidermal growth factor receptor (anti-EGFR) antibody conjugated fluorescent nanoparticles probe for breast cancer imaging. Spectrochim Acta A Mol Biomol Spectrosc 2009; 74 (2): 410-414.
44. Yang J, Lee C-H, Park J, Seo S, Lim E-K, Song YJ, Suh J-S, Yoon H-G, Huh Y-M, Haam S,. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007; 17 (26): 2695.
45. Yang HM, Park CW, Woo MA, Kim MI, Jo YM, Park HG, Kim JD,. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging. Biomacromolecules 2010; 11 (11): 2866-2872.
46. 4 nanoparticles for targeted bi-modal imaging of pancreatic cancer. J Mater Chem 2011; 21 (34): 12650.
47. Lim E-K, Jang E, Kim B, Choi J, Lee K, Suh J-S, Huh Y-M, Haam S,. Dextran-coated magnetic nanoclusters as highly sensitive contrast agents for magnetic resonance imaging of inflammatory macrophages. J Mater Chem 2011; 21 (33): 12473.
48. Lim EK, Kim HO, Jang E, Park J, Lee K, Suh JS, Huh YM, Haam S,. Hyaluronan-modified magnetic nanoclusters for detection of CD44-overexpressing breast cancer by MR imaging. Biomaterials 2011; 32 (31): 7941-7950.
49. Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, Cheng Z,. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 2011; 32 (8): 2141-2148.
50. Gee MS, Upadhyay R, Bergquist H, Alencar H, Reynolds F, Maricevich M, Weissleder R, Josephson L, Mahmood U,. Human breast cancer tumor models: Molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 2008; 248 (3): 925-935.
51. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN,. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008; 130 (28): 9137-9143.
52. Jayasena SD,. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999; 45 (9): 1628-1650.
53. Barbas AS, Mi J, Clary BM, White RR,. Aptamer applications for targeted cancer therapy. Future Oncol 2010; 6 (7): 1117-1126.
54. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S,. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011; 7 (15): 2241-2249.
55. Chen T, Shukoor MI, Wang R, Zhao Z, Yuan Q, Bamrungsap S, Xiong X, Tan W,. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano 2011; 5 (10): 7866-7873.
56. Donovan MJ, Meng L, Chen T, Zhang Y, Sefah K, Tan W,. Aptamer-drug conjugation for targeted tumor cell therapy. Methods Mol Biol 2011; 764: 141-152.
57. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S,. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010; 31 (16): 4592-4599.
58. Kong RM, Zhang XB, Chen Z, Tan W,. Aptamer-assembled nanomaterials for biosensing and biomedical applications. Small 2011; 7: 2428-2436.
59. Kim MY, Jeong S,. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 2011; 21 (3): 173-178.
60. Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008; 3 (9): 1311-1315.
61. Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, Jiang X, Yao L, Chen J, Chen H,. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011; 32 (31): 8010-8020.
62. Min K, Jo H, Song K, Cho M, Chun YS, Jon S, Kim WJ, Ban C,. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 2011; 32 (8): 2124-2132.
63. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC,. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007; 2 (9): 1268-1271.
64. Zheng D, Seferos DS, Giljohann DA, Patel PC, Mirkin CA,. Aptamer nano-flares for molecular detection in living cells. Nano Lett 2009; 9 (9): 3258-3261.
65. 4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004; 126 (1): 273-279.
66. Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM,. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel. Invest Radiol 2011; 46 (7): 441-449.
67. Lim EK, Huh YM, Yang J, Lee K, Suh JS, Haam S,. pH-triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv Mater 2011; 23 (21): 2436-2442.
68. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S,. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed 2007; 46 (46): 8836-8839.
69. Yang J, Lim EK, Lee HJ, Park J, Lee SC, Lee K, Yoon HG, Suh JS, Huh YM, Haam S,. Fluorescent magnetic nanohybrids as multimodal imaging agents for human epithelial cancer detection. Biomaterials 2008; 29 (16): 2548-2555.
70. Yang J, Lee J, Kang J, Oh SJ, Ko H-J, Son J-H, Lee K, Suh J-S, Huh Y-M, Haam S,. Smart drug-loaded polymer gold nanoshells for systemic and localized therapy of human epithelial cancer. Adv Mater 2009; 21 (43): 4339-4342.
71. Choi J, Yang J, Park J, Kim E, Suh J-S, Huh Y-M, Haam S,. Specific near-IR absorption imaging of glioblastomas using integrin-targeting gold nanorods. Adv Funct Mater 2011; 21 (6): 1082-1088.
72. Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY,. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322 (2): 560-568.
73. Ruoslahti E,. The RGD story: A personal account. Matrix Biol 2003; 22 (6): 459-465.
74. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD,. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci USA 1991; 88 (13): 5819-5823.
75. Albanese A, Tang PS, Chan WC,. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012; 14: 1-16.
76. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P,. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 2011; 6 (9): e24374-e24374.
77. Li S-D, Huang L,. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5 (4): 496-504.